Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Healsea® Children Isotonic Nasal Spray in the Prevention of Upper Respiratory Tract Infections With Nasal Symptoms in Children: a Pre-market Study

NCT06582589 is registered in ClinicalTrials.gov with Lallemand Pharma AG as lead sponsor.

NCT NCT06582589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06582589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Healsea® Children Isotonic Nasal Spray in the Prevention of Upper Respiratory Tract Infections With Nasal Symptoms in Children: a Pre-market Study
Lead sponsor
Lallemand Pharma AG
Phase
Phase 2/3
Overall status
Completed
Start date
November 25, 2024
Completion date
April 23, 2025
Enrollment
139 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects